Genedrive Reports Progress in Pharmacogenetic Testing Amid Interim Results

The latest update is out from Genedrive ( (GB:GDR) ).

Genedrive plc has reported its interim results for the six months ending December 31, 2024, highlighting significant advancements in its pharmacogenetic testing products. The company achieved its first UK commercial sales of the Genedrive® CYP2C19-ID Kit and secured a positive assessment from the Scottish Health Technologies Group, leading to government investment in national pharmacogenetic testing. Additionally, Genedrive’s MT-RNR1 ID Kit received funding for implementation in newborns across NHS Scotland, preventing hearing loss in infants. The company is expanding its operational capabilities and market reach, with a focus on increasing sales and distribution networks both domestically and internationally. Despite reporting an operating loss, Genedrive is optimistic about its future growth prospects and the increasing adoption of its testing kits, which promise significant cost savings and improved patient outcomes.

More about Genedrive

Genedrive plc is a UK-based pharmacogenetic testing company specializing in rapid, low-cost point-of-care genetic testing platforms. The company focuses on diagnosing genetic variants to aid clinicians in making informed decisions about medication and dosages, particularly in emergency healthcare settings. Genedrive has developed two flagship products: the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both designed for quick and effective genetic testing in critical care scenarios.

YTD Price Performance: -25.51%

Average Trading Volume: 2,988,867

Technical Sentiment Signal: Strong Buy

Current Market Cap: £9.91M

Find detailed analytics on GDR stock on TipRanks’ Stock Analysis page.